Associated tags: Knowledge, Health, Medicine, Health Technology, Research, Software, Science, Biotechnology, Pharmaceutical industry, Doctor of Philosophy, Oncology, Genetics, Pharmaceutical, MD, Clinical Trials, Patient, AI, Drug discovery, Ecosystem
Locations: BOSTON, DISTRICT OF COLUMBIA, WASHINGTON, UNITED STATES, NORTH AMERICA, MASSACHUSETTS, US, EUROPE, AUSTRALIA
Other Health,
General Health,
Radiology,
Pharmaceutical,
Medical Devices,
Technology,
Hospitals,
Artificial Intelligence,
Genetics,
Health Technology,
Biotechnology,
Health,
Genomics,
Algorithm,
MRI,
FHIR,
Down syndrome,
Environment,
Investigation,
Disease,
Patient,
Artificial intelligence,
AI,
PB,
NIH,
Ecosystem,
Privacy,
Government,
Syndrome,
Metadata,
Medical imaging Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
Key Points:
- Combining their capabilities, Velsera, Flywheel, and D3b were able to manage, harmonize, and analyze large datasets in a cloud-based platform.
- The Velsera team created interoperability standards that allow platforms to communicate with each other and make large-scale data access transparent to the user.
- “Linking our Flywheel Core Platform with Velsera’s CAVATICA platform facilitates an unparalleled ability to perform advanced, multimodal data analysis in a cloud environment,” said Travis Richardson, Chief Strategist at Flywheel.
- Using data from D3b, teams were able to analyze the combination of extracted imaging features on the Flywheel Core Platform.
Health,
Technology,
Other Technology,
Health Technology,
Pharmaceutical,
Biotechnology,
Therapy,
Multimedia,
Summa,
Drug discovery,
Partner,
Computational biology,
Medicine,
McKinsey & Company Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024.
Key Points:
- Velsera, a pioneering entity in the field of computational biology with a focus on advancing precision medicine, is delighted to formally announce the appointment of Jamie Littlejohns as its Chief Executive Officer, with his tenure commencing on the 1st of March, 2024.
- Jamie is set to succeed Hans Cobben, who has served as the interim CEO and will revert to his position as Chairman of the Board at Velsera.
- In his own words, Jamie says, "I am thrilled to be joining the wonderful team at Velsera.
- Furthermore, his prior experience with both Summa and Velsera enables him to hit the ground running, providing continuity whilst injecting his unique energy into Velsera.
Retrieved on:
Wednesday, November 15, 2023
Data Management,
Biotechnology,
Technology,
Health,
General Health,
Oncology,
Health Technology,
Research,
Software,
Genetics,
Science,
Complement,
Annual general meeting,
Weill Cornell Medicine,
Patient,
Memory,
Workflow,
CGW,
Doctor of Philosophy,
NGS,
Biomarker,
AMP,
Microsatellite instability,
Medical imaging,
MD Velsera's latest offering combines expertly curated evidence, dynamic interpretations and adaptive behavior to drive significantly shorter signout times and smarter clinical interpretation.
Key Points:
- Velsera's latest offering combines expertly curated evidence, dynamic interpretations and adaptive behavior to drive significantly shorter signout times and smarter clinical interpretation.
- Memory of Biomarker Reporting Decisions: Velsera's CGW can now remember and reuse biomarker reporting decisions, including interpretations and reported treatment options.
- CGW is an all-in-one analysis and reporting tool for clinical NGS data, based on an industry-leading knowledgebase, robust clinical reporting and tailored lab services.
- “High Quality, Automated Oncology ‘Omics Reporting with Velsera’s Knowledgebase”, presented by Will Moller, director of product management at Velsera.
Biotechnology,
Practice Management,
Oncology,
General Health,
Health,
Health Technology,
Genetics,
Other Health,
Patient,
DSM-IV codes,
Genetic testing,
Physician,
CGW,
Doctor of Philosophy,
Trust,
NGS,
Risk,
Partnership,
Cancer,
Diagnosis,
DNA,
Pharmaceutical industry,
MD Solaris Health is proud that its affiliated urology practices are the first to afford their patients the ability to receive in-house genetic testing.
Key Points:
- Solaris Health is proud that its affiliated urology practices are the first to afford their patients the ability to receive in-house genetic testing.
- The partnership with Velsera, which provided critical technology, services and expertise, has furthered the goal to expand access to this guideline-based testing across the nation.
- Inherited cancer testing looks for DNA variants inherited from an individual’s parents that would predispose them to develop certain kinds of cancer.
- The partnership with Velsera has greatly accelerated the ability of affiliated practices to offer this vital genetic testing to patients," said Solaris Chairman Deepak Kapoor, MD.
Retrieved on:
Thursday, November 2, 2023
Biotechnology,
Technology,
Health,
Pharmaceutical,
Oncology,
Research,
Software,
Artificial Intelligence,
Genetics,
Science,
Clinical Trials,
Data analysis,
Acceleration,
Doctor of Philosophy,
Genomics,
NVIDIA,
Medicine,
Drug discovery,
Seven Bridges,
Pharmaceutical industry Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is collaborating with NVIDIA to bring the NVIDIA Parabricks software suite to its Seven Bridges Platform.
Key Points:
- Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is collaborating with NVIDIA to bring the NVIDIA Parabricks software suite to its Seven Bridges Platform.
- The Parabricks tools are integrated into the Velsera bioinformatics platform through the Seven Bridges Public Apps Gallery .
- With its integration, 16,000+ researchers around the world who collaborate through the Seven Bridges Platform can now access NVIDIA’s AI expertise and healthcare computing platforms.
- The availability of Parabricks on Seven Bridges supports Velsera’s mission to expand access to genomic sequencing analysis and foster innovation.
Retrieved on:
Wednesday, October 4, 2023
Health,
Technology,
Health Technology,
Software,
Research,
Science,
Artificial Intelligence,
Cloud,
Pharma,
QC,
Drug discovery,
Google Cloud Platform,
Clinical trial,
Leverage,
Medicine,
Novo Nordisk,
Azure,
Ecosystem,
Congress,
AI,
AWS,
Automation,
Data science,
Pharmaceutical industry,
Medical device,
Video game Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to announce its title sponsorship at BioTechX Europe in Basel, Switzerland, where it will showcase its industry-leading Seven Bridges bioinformatics platform.
Key Points:
- Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to announce its title sponsorship at BioTechX Europe in Basel, Switzerland, where it will showcase its industry-leading Seven Bridges bioinformatics platform.
- This conference is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare.
- His talk is at 12:05 pm on Thursday, Oct. 5, as part of the bioinformatics track.
- Velsera’s bioinformatics platform powers the healthcare and life sciences ecosystem with data and insights made actionable by AI.
Biotechnology,
Technology,
Managed Care,
Health,
Pharmaceutical,
Oncology,
Health Technology,
Research,
Software,
Science,
Clinical Trials,
Molecular biology,
Amgen,
Human,
University,
SVKM's NMIMS,
Biochemistry,
Marketing,
Brake,
Quality of life,
Coty,
MBA,
Medicine,
Kellogg School,
Doctor of Philosophy,
Organization,
MAC,
Takeda Oncology,
Patient,
Love,
MAC Cosmetics,
Northwestern University,
Nursing,
Management,
Unilever “I find what Velsera is doing -- to power precision oncology to marry the medicine to the patient -- very inspiring,” Brake said. “Given my professional background working across discovery research, clinical development and medical affairs, I understand where the roadblocks to this vision might be. I look forward to helping to develop strategies to define where Velsera can bring value to these kinds of customers and the patients they serve.”
Key Points:
- Velsera , a healthcare technology company offering a universal software platform to connect clinical care with discovery, today announced the addition of Rachael Brake, PhD, and Ukonwa Ojo to its board of directors.
- Brake is a distinguished scientist with more than 20 years of experience in R&D, global clinical development and medical affairs.
- She serves as the chief scientific officer of Corbus Pharmaceuticals, a precision oncology company, and prior to that she worked in leading roles at Takeda Oncology and Amgen.
- “I find what Velsera is doing -- to power precision oncology to marry the medicine to the patient -- very inspiring,” Brake said.
Software,
Research,
Pharmaceutical,
Data Management,
Technology,
Hospitals,
Genetics,
Health Technology,
Clinical Trials,
Science,
Biotechnology,
Health,
Data management,
Virology,
Personalized medicine,
Doctor of Philosophy,
ARIA,
MD,
Molecular Partners,
Medicine,
Drug discovery,
Pharmaceutical industry Velsera, a healthcare technology company that offers a universal software platform to connect clinical care with research and development, is pleased to announce its presence at the Bio-IT World conference May 17-18 in Boston.
Key Points:
- Velsera, a healthcare technology company that offers a universal software platform to connect clinical care with research and development, is pleased to announce its presence at the Bio-IT World conference May 17-18 in Boston.
- The company will be showcasing its industry-leading bioinformatics products and platforms, including the new features of its ARIA solution.
- “There is flexibility for collaborating with a diverse range of internal and external stakeholders — securely, seamlessly and at scale.
- Visit the Velsera booth #413 at the Bio-IT World conference to learn more about Velsera’s core capabilities: genomics analysis, clinical reporting, scalable laboratory workflow orchestration and diverse, interoperable data management and exploration.
Software,
Technology,
Health Technology,
Health,
Komodo,
Therapy,
Mandarin Oriental Hotel Group,
ML,
Machine learning,
Hearing,
Medicine,
FACS,
Ecosystem,
AI,
Medical device,
MD The summit’s two-day lineup of notable speakers will highlight advances and areas of collaboration in precision medicine across R&D, clinical diagnostics, healthcare technology, assay development, patient registries and public programs.
Key Points:
- The summit’s two-day lineup of notable speakers will highlight advances and areas of collaboration in precision medicine across R&D, clinical diagnostics, healthcare technology, assay development, patient registries and public programs.
- Velsera convened this program to showcase the potential power of a connected ecosystem of diverse data, insights and expertise.
- Participants share Velsera’s interest in accelerating target identification, new therapy development, clinical trials optimization and ‘omics-driven diagnostics and decision support at scale.
- “The use of AI and ML in healthcare has accelerated substantially in recent years, particularly in developing highly targeted therapeutics and diagnostics.
Retrieved on:
Thursday, January 12, 2023
Environment,
Pharmaceutical,
Research,
Oncology,
Sustainability,
Software,
Finance,
Medical Devices,
Environmental, Social and Governance (ESG),
Genetics,
Professional Services,
Science,
Technology,
Clinical Trials,
Data Analytics,
Biotechnology,
Health,
Health Technology,
Unisys,
Ecosystem,
Algorithm,
UN,
Calyx,
IQVIA,
Laboratory,
Medical imaging,
Precision medicine,
Machine learning,
Knowledge,
Health,
AI,
Conference,
Informatics,
Seven Bridges,
PCR,
Patient,
Research,
Data analysis,
Innovation,
Acquisition,
Summa,
Pharmaceutical industry,
Capgemini,
Pierian Spring,
Parexel The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
Key Points:
- The vision for Velsera is supported by thematic-focused impact fund Summa Equity (“Summa”).
- The promise of precision medicine is held back by barriers across routine health practice and discovery.
- Velsera sets out to amplify the impact of clinicians, researchers and scientists for the benefit of patients around the world.
- Velsera unites these companies to advance and bring together their missions which are centered around improving health globally through multi-omics and insights.
